Skip to search formSkip to main contentSkip to account menu

Megace

Known as: Bristol-Myers Squibb Brand of Megestrol Acetate, Squibb Brand of Megestrol Acetate, Bristol Myers Squibb Brand of Megestrol Acetate 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

MegestrolMegestrol Acetate
Megestrol Acetate 125 MG/ML Oral Suspension [Megace]Megestrol Oral Suspension [Megace]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
Aim: Whether high platelet reactivity (HPR) immediately after diagnostic angiography is associated with worse coronary… 
Review
2015
Review
2015
Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States
T he current estimates of chronic hepatitis B (CHB) and chronic hepatitis C (CHC) prevalence that are widely used by the press… 
2015
2015
Evaluation of medical costs avoided when new oral anticoagulants are used for extended treatment of venous thromboembolism based on clinical trial results
This study evaluated avoidances in medical costs associated with clinical endpoints from randomized clinical trials that… 
Review
2013
Review
2013
An Updated Review of Target‐Specific Oral Anticoagulants Used in Stroke Prevention in Atrial Fibrillation, Venous Thromboembolic Disease, and Acute Coronary Syndromes
Atrial fibrillation (AF) is a common arrhythmia in the adult population. It is associated with up to a 5-fold increased risk of… 
Review
2012
Review
2012
Cardiovascular disease and diabetes: the vulnerable patient
Patients with diabetes exhibit an increased risk for cardiovascular complications, such as acute coronary syndromes, stroke… 
Review
2006
Review
2006
Insurance Coverage and Care of Patients with NonST-Segment Elevation Acute Coronary Syndromes
Context Medicaid and Medicare reimbursement is typically lower than that of private insurance. This might affect access to care… 
2006
2006
Funding for accelerating drug development initiative critical
FDA's Critical Path Initiative needs industry resources to succeed 
1998
1998
The first total synthesis of natural (+)-terpestacin, syncytium formation inhibitor.
Sir: During the search for drugs to cure AIDS, BristolMyers Squibb's group has isolated terpestacin (1) from culture broth of… 
1994
1994
Circadian rhythm modulated 5‐FUdR infusion with megace in the treatment of advanced pancreatic cancer
Thirteen patients with advanced pancreatic carcinoma were treated with circadian rhythm modulated infusion of 5‐FUdR and Megace… 
Highly Cited
1984
Highly Cited
1984
Multidrug Treatment of Advanced and Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study
Patients (358) with advanced (FIGO stages III and IV) or recurrent endometrial cancer were treated with one of two regimens: 1… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)